OncoResponse, a Seattle, WA-based immunotherapy company developing a portfolio of novel antibodies to high-value targets for the treatment of cancer, completed a $40m series B equity financing.
The round was led by RiverVest Venture Partners, with participation from new investors Qatar Investment Authority (QIA) and Redmile Group, and existing investors Alexandria Venture Investments, ARCH Venture Partners, HT Family Office, Canaan Partners, Helsinn Investment Fund and William Marsh Rice University.
The company intends to use the funds to advance its five drug candidates into preclinical and clinical development.
Led by Clifford J. Stocks, CEO, OncoResponse discovers and develops targeted and immuno-oncology therapeutic antibodies against novel cancer targets. The company’s discovery engine is working to increase the success rate of cancer immunotherapies by identifying novel antibody drug candidates across multiple cancer types from the immune systems of patients who have responded well to cancer immunotherapies.